VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

  • Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates and bispecific antibodies targeting ROR1, a novel oncology target, across multiple cancer types
  • Lead investors Matrix Capital Management and Surveyor Capital (a Citadel company) are joined by Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, Wellington Management Company, and all existing institutional investors

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...